Global chemical effects of the microbiome include new bile-acid conjugations
- Creators
- Quinn, Robert A.
- Melnik, Alexey V.
- Vrbanac, Alison
- Fu, Ting
- Patras, Kathryn A.
- Christy, Mitchell P.
- Bodai, Zsolt
- Belda-Ferre, Pedro
- Tripathi, Anupriya
- Chung, Lawton K.
- Downes, Michael
- Welch, Ryan D.
- Quinn, Melissa
- Humphrey, Greg
- Panitchpakdi, Morgan
- Weldon, Kelly C.
- Aksenov, Alexander
- da Silva, Ricardo
- Avila-Pacheco, Julian
- Clish, Clary
- Bae, Sena
- Mallick, Himel
- Franzosa, Eric A.
- Lloyd-Price, Jason
- Bussell, Robert
- Thron, Taren
- Nelson, Andrew T.
- Wang, Mingxun
- Leszczynski, Eric
- Vargas, Fernando
- Gauglitz, Julia M.
- Meehan, Michael J.
- Gentry, Emily
- Arthur, Timothy D.
- Komor, Alexis C.
- Poulsen, Orit
- Boland, Brigid S.
- Chang, John T.
- Sandborn, William J.
- Lim, Meerana
- Garg, Neha
- Lumeng, Julie C.
- Xavier, Ramnik J.
- Kazmierczak, Barbara I.
- Jain, Ruchi
- Egan, Marie
- Rhee, Kyung E.
- Ferguson, David
- Raffatellu, Manuela
- Vlamakis, Hera
- Haddad, Gabriel G.
- Siegel, Dionicio
- Huttenhower, Curtis
- Mazmanian, Sarkis K.
- Evans, Ronald M.
- Nizet, Victor
- Knight, Rob
- Dorrestein, Pieter C.
Abstract
A mosaic of cross-phylum chemical interactions occurs between all metazoans and their microbiomes. A number of molecular families that are known to be produced by the microbiome have a marked effect on the balance between health and disease. Considering the diversity of the human microbiome (which numbers over 40,000 operational taxonomic units), the effect of the microbiome on the chemistry of an entire animal remains underexplored. Here we use mass spectrometry informatics and data visualization approaches to provide an assessment of the effects of the microbiome on the chemistry of an entire mammal by comparing metabolomics data from germ-free and specific-pathogen-free mice. We found that the microbiota affects the chemistry of all organs. This included the amino acid conjugations of host bile acids that were used to produce phenylalanocholic acid, tyrosocholic acid and leucocholic acid, which have not previously been characterized despite extensive research on bile-acid chemistry. These bile-acid conjugates were also found in humans, and were enriched in patients with inflammatory bowel disease or cystic fibrosis. These compounds agonized the farnesoid X receptor in vitro, and mice gavaged with the compounds showed reduced expression of bile-acid synthesis genes in vivo. Further studies are required to confirm whether these compounds have a physiological role in the host, and whether they contribute to gut diseases that are associated with microbiome dysbiosis.
Additional Information
© 2020 Springer Nature Limited. Received 06 July 2018; Accepted 03 January 2020; Published 26 February 2020. The authors acknowledge funding from the National Institutes of Health (NIH), grants 5U01AI124316-03, 1R03CA211211-01, 1R01HL116235 U54DE023798, R24DK110499, GMS10RR029121, 1 DP1 AT010885, P30 DK120515 and R01HD084163. Additionally, B.S.B. was supported by UCSD KL2 (1KL2TR001444), T.D.A. by the National Library of Medicine Training Grant NIH grant T15LM011271. R.M.E. is an investigator of the Howard Hughes Medical Institute and March of Dimes Chair in Molecular and Developmental Biology at the Salk Institute. R.M.E. was funded by grants from the NIH (DK057978, HL105278, HL088093 and ES010337), and Samuel Waxman Cancer Research Foundation. We acknowledge G. Ackermann for her contributions. This work was also supported in part by Seed Grants from the UC San Diego Center for Microbiome Innovation. This work was funded by grants from the NIH (DK057978, HL105278 and HL088093), National Cancer Institute (CA014195), the Leona M. and Harry B. Helmsley Charitable Trust (2017PG-MED001), SWCRF Investigator Award and Ipsen/Biomeasure. J.L. is supported by grant EIA14660045, an American Heart Association Established Investigator Award. T.F. is supported by a Hewitt Medical Foundation Fellowship, a Salk Alumni Fellowship. T.F., R.K. and P.C.D. acknowledge support from the Crohn's & Colitis Foundation (CCFA). R.M.E. and M.D. are supported in part by a Stand Up to Cancer (SU2C) - Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Research Grant (SU2C-AACR-DT-20-16). SU2C is a programme of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. Research reported in this publication was also supported by the National Institute of Environmental Health Sciences of the NIH under Award Number P42ES010337. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Data availability: All metabolomics data that support the findings of this study are available at GNPS (https://gnps.ucsd.edu/) under MassIVE ID numbers: MSV000079949 (original germ-free and SPF mouse data), MSV000082480, MSV000082467, MSV000079134, MSV000082406, MSV000083032, MSV000083004 and MSV000083446. The sequencing data for the germ-free and SPF mouse study are available on the Qiita microbiome data analysis platform at https://qiita.ucsd.edu/ under study ID 10801 and through the European Bioinformatics Institute accession number ERP109688. Source Data for Figs. 1–3, Extended Data Fig. 7 are provided with the paper. Code availability: MASST can be accessed at https://masst.ucsd.edu/; the development of MASST is described in ref. 43. The code for MS/MS-based MASST searching is available at https://github.com/CCMS-UCSD/GNPS_Workflows/tree/master/search_single_spectrum. Author Contributions: P.C.D., R.K. and R.A.Q. designed the project. P.C.D. and R.A.Q. discovered the bile acids. R.A.Q., A.A., A.V.M., F.V., J.M.G., N.G., A.T., M.P.C., L.K.C., A.T.N., M.J.M., G.H., M.P., C.C., S.B., E.G., K.C.W., P.B.-F., H.M., E.A.F., H.V., J.L.-P., T.D.A., A.C.K., J.A.-P., Z.B., E.L., M.Q., T.F., R.D.W., D.F., G.G.H. and R.B. generated data. R.A.Q., A.V., A.T., Z.B., A.V.M., R.d.S., R.J.X., T.F., R.D.W., M.D., R.M.E. and M.P.C. analysed data. R.A.Q., B.S.B., M.L., O.P., J.T.C., M.L., J.C.L., K.A.P., B.I.K., R.J., M.E., K.E.R., G.H., C.C., W.J.S. and R.B. collected samples. D.S., E.G., M.P.C. and A.T.N. were responsible for chemical synthesis. T.F., R.D.W., M.D. and R.M.E. were responsible for the FXR in vitro and in vivo functional studies and analysis, and edited the paper. P.C.D., R.K., S.K.M., V.N., C.H., R.J.X., A.C.K. and D.S. guided experimental design and analysis. M.W. converted the data in GNPS and developed MASST spectral search. T.T., V.N., M.R. and S.K.M. raised mice and guided experimental design. R.A.Q. and P.C.D. wrote the manuscript. Competing interests: C.H. is on the scientific advisory board of Seres Therapeutics. M.W. is founder of, and A.A. is a consultant for, Ometa Laboratories LLC. P.C.D. and M.W. are consultants for Sirenas Therapeutics. W.J.S. consults for Abbvie, Allergan, Amgen, Arena Pharmaceuticals, Avexegen Therapeutics, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead Sciences, Gossamer Bio, Incyte, Janssen, Kyowa Kirin Pharmaceutical Research, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pfizer, Progenity, Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories), Reistone, Ritter Pharmaceuticals, Robarts Clinical Trials (owned by Health Academic Research Trust, HART), Series Therapeutics, Shire, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance Biopharma, Tigenix, Tillotts Pharma, UCB Pharma, Ventyx Biosciences, Vimalan Biosciences and Vivelix Pharmaceuticals; and holds stock or stock options from BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan Pharma, Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories), Progenity, Ritter Pharmaceuticals, Ventyx Biosciences and Vimalan Biosciences.Attached Files
Supplemental Material - 41586_2020_2047_Fig10_ESM.jpg.webp
Supplemental Material - 41586_2020_2047_Fig11_ESM.jpg.webp
Supplemental Material - 41586_2020_2047_Fig12_ESM.jpg.webp
Supplemental Material - 41586_2020_2047_Fig4_ESM.jpg.webp
Supplemental Material - 41586_2020_2047_Fig5_ESM.jpg.webp
Supplemental Material - 41586_2020_2047_Fig6_ESM.jpg.webp
Supplemental Material - 41586_2020_2047_Fig7_ESM.jpg.webp
Supplemental Material - 41586_2020_2047_Fig8_ESM.jpg.webp
Supplemental Material - 41586_2020_2047_Fig9_ESM.jpg.webp
Supplemental Material - 41586_2020_2047_MOESM1_ESM.pdf
Supplemental Material - 41586_2020_2047_MOESM2_ESM.pdf
Supplemental Material - 41586_2020_2047_MOESM3_ESM.xlsx
Supplemental Material - 41586_2020_2047_MOESM4_ESM.xlsx
Supplemental Material - 41586_2020_2047_MOESM5_ESM.xlsx
Supplemental Material - 41586_2020_2047_MOESM6_ESM.xlsx
Supplemental Material - 41586_2020_2047_MOESM7_ESM.xlsx
Supplemental Material - 41586_2020_2047_MOESM8_ESM.xlsx
Files
Name | Size | Download all |
---|---|---|
md5:84bc38db1e4060e275d40c233fb73402
|
296.4 kB | Download |
md5:c9e8c7524b18212866114c086792a97e
|
6.0 MB | Download |
md5:60b3c44e5643dfa29443a74c02d99d3f
|
28.5 kB | Download |
md5:0cbb50b12a831bb4f4f5254ee635dc9e
|
11.0 kB | Download |
md5:d5cfd88c403db27367aa6c4c19036518
|
155.5 kB | Download |
md5:02eab7ebb474dbc75d9c3670112e1ea7
|
52.2 kB | Download |
md5:a60b10eff9ee2a46689b8878185b6436
|
294.4 kB | Download |
md5:d4ab45d36bcc4ab4b2e2a22ee7e5e8b2
|
212.1 kB | Download |
md5:4442ef6382b1299028753cfa022161d4
|
139.4 kB | Preview Download |
md5:a5b5dc56da6b3910710f8e3fb8889bac
|
1.2 MB | Preview Download |
md5:22c9d84bb8b237ea349dc8928af68839
|
315.7 kB | Download |
md5:874e82bb8b99e5e5c59f51fee5fd76f4
|
11.4 kB | Download |
md5:c61edce351a73be69d07e6fc30e3828d
|
63.7 kB | Download |
md5:33d7be0985d764dbcb42d25e351307ba
|
165.7 kB | Download |
md5:ad73bc4092b6400134fbb3cace523f25
|
83.1 kB | Download |
md5:79f3cbfb74765acc578edebbe753a8a5
|
429.8 kB | Download |
md5:9c5c5d533598530ebfc1c290cd36b56a
|
328.1 kB | Download |
Additional details
- Eprint ID
- 101682
- DOI
- 10.1038/s41586-020-2047-9
- Resolver ID
- CaltechAUTHORS:20200303-123932684
- NIH
- 5U01AI124316-03
- NIH
- 1R03CA211211-01
- NIH
- 1R01HL116235
- NIH
- U54DE023798
- NIH
- R24DK110499
- NIH
- GMS10RR029121
- NIH
- 1 DP1 AT010885
- NIH
- P30 DK120515
- NIH
- R01HD084163
- University of California, San Diego
- 1KL2TR001444
- NIH Predoctoral Fellowship
- T15LM011271
- Howard Hughes Medical Institute (HHMI)
- March of Dimes Foundation
- NIH
- DK057978
- NIH
- HL105278
- NIH
- HL088093
- NIH
- ES010337
- Samuel Waxman Cancer Research Foundation
- NIH
- CA014195
- Leona M. and Harry B. Helmsley Charitable Trust
- 2017PG-MED001
- SWCRF Investigator Award
- Ipsen/Biomeasure
- American Heart Association
- EIA14660045
- Hewitt Medical Foundation Fellowship
- Salk Institute
- Crohn's and Colitis Foundation of America
- Cancer Research UK-Lustgarten Foundation
- SU2C-AACR-DT-20-16
- Entertainment Industry Foundation
- American Association for Cancer Research
- NIH
- P42ES010337
- Created
-
2020-03-03Created from EPrint's datestamp field
- Updated
-
2021-11-16Created from EPrint's last_modified field
- Caltech groups
- Division of Biology and Biological Engineering